Marina Biotech, Inc. to Present at The 13th Annual BIO CEO & Investor Conference

BOTHELL, WA--(Marketwire - February 8, 2011) -  Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will present at The 13^th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) at the Waldorf-Astoria in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update. 

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Contact Information:

Contact:
Marina Biotech, Inc.:
Pete Garcia
Chief Financial Officer
(425) 908-3603